The goal of this clinical trial is to evaluate whether Viv, a consumer-grade dietary supplement derived from the Magnolia officinalis plant, has an effect on biomarkers of immune activity in adults with psoriasis. To address this question, this trial will compare Viv to a placebo (a look-alike substance that contains no drug). Participants will: * Take Viv or a placebo every day for 3 months. * Complete electronic questionnaires about their quality of life and psoriasis symptoms at the beginning of the study and again at 1 months and 3 months. * Be provided with at home blood collection kits, which they will use to collect blood at the beginning of the study and again at 1 months and 3 months. Researchers will analyze these blood samples to measure the levels of specific inflammatory proteins and evaluate how they change over the course of the study in the participants taking Viv compared to those taking placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
100
Viv is a consumer grade oral supplement containing 200mg Magnolia officinalis bark extract encapsulated in a hypromellose capsule.
Oral hypromellose capsule with all inactive ingredients but lacking the Magnolia officinalis bark extract
Decentralized Study Coordinating Center
Englewood, New Jersey, United States
RECRUITINGRelative change in plasma Beta defensin 2 from baseline
Change in plasma Beta defensin 2 levels between placebo and study product group at 4 weeks and 12 weeks relative to baseline as measured by ELISA
Time frame: From baseline to the end of study product/placebo use at 12 weeks
Exploratory analyses of serum proteomics
Change in plasma cytokine levels between placebo and study product groups at 4 weeks and 12 weeks relative to baseline as measured by high throughput plasma proteomics
Time frame: Baseline to end of study product/placebo use at 12 weeks
Exploratory analysis of circulating immune cells
Change in proportions and activity of peripheral blood immune cells between placebo and study product groups at 12 weeks relative to baseline as measured by single cell sequencing
Time frame: Baseline to end of study product/placebo use at 12 weeks
Quality of life assessment
Change in quality of life between placebo and study product group at 4, and 12 weeks relative to baseline as measured by self-reported Dermatology Life Quality Index (DLQI)
Time frame: Baseline to end of study product/placebo use at 12 weeks
Self reported psoriasis symptoms
Change in self-reported psoriasis symptoms between placebo and study group at 12 weeks relative to baseline as measured by Psoriasis Symptom Scale (PSS)
Time frame: Baseline to end of study product/placebo use at 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.